- Home
- OMCL vs NVCR Comparison
OMCL vs NVCR Comparison
Compare OMCL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- NVCR
- Stock Information
- Founded
- OMCL 1992
- NVCR 2000
- Country
- OMCL United States
- NVCR Switzerland
- Employees
- OMCL N/A
- NVCR N/A
- Industry
- OMCL Computer Manufacturing
- NVCR Medical/Dental Instruments
- Sector
- OMCL Technology
- NVCR Health Care
- Exchange
- OMCL Nasdaq
- NVCR Nasdaq
- Market Cap
- OMCL 1.3B
- NVCR 1.9B
- IPO Year
- OMCL 2001
- NVCR 2015
- Fundamental
- Price
- OMCL $28.69
- NVCR $17.60
- Analyst Decision
- OMCL Buy
- NVCR Buy
- Analyst Count
- OMCL 6
- NVCR 7
- Target Price
- OMCL $44.83
- NVCR $32.43
- AVG Volume (30 Days)
- OMCL 415.8K
- NVCR 1.4M
- Earning Date
- OMCL 07-31-2025
- NVCR 07-24-2025
- Dividend Yield
- OMCL N/A
- NVCR N/A
- EPS Growth
- OMCL N/A
- NVCR N/A
- EPS
- OMCL 0.45
- NVCR N/A
- Revenue
- OMCL $1,135,755,000.00
- NVCR $621,711,000.00
- Revenue This Year
- OMCL $3.84
- NVCR $5.56
- Revenue Next Year
- OMCL $3.98
- NVCR $9.19
- P/E Ratio
- OMCL $63.65
- NVCR N/A
- Revenue Growth
- OMCL 3.00
- NVCR 18.27
- 52 Week Low
- OMCL $22.66
- NVCR $14.17
- 52 Week High
- OMCL $55.75
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- OMCL 43.98
- NVCR 49.74
- Support Level
- OMCL $28.81
- NVCR $16.81
- Resistance Level
- OMCL $30.19
- NVCR $18.59
- Average True Range (ATR)
- OMCL 0.88
- NVCR 0.74
- MACD
- OMCL 0.02
- NVCR 0.08
- Stochastic Oscillator
- OMCL 34.49
- NVCR 56.18
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.